OSLO, Norway, March 12, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the company will be presenting at the following upcoming investor conferences:
For further information, please contact:
IR enquiries Malene Brondberg, VP, Investor Relations and Corporate Communications Tel/Cell: + 44-7561-431-762 Email: [email protected]
Media enquiries Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: [email protected]
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-to-present-at-the-china-healthcare-investing---partnering-symposium-in-china-and-s,c2469759
Advertisement
- The China Healthcare Investing & Partnering Symposium (CHIPS) in Hangzhou, China (15-17 March)
- Stifel Nordic Healthcare Seminar in London, UK (20 March)
Advertisement
For further information, please contact:
IR enquiries Malene Brondberg, VP, Investor Relations and Corporate Communications Tel/Cell: + 44-7561-431-762 Email: [email protected]
Media enquiries Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson) Tel: +44-207-638-9571 Email: [email protected]
About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications. Further information about the Company can be found at www.nordicnanovector.com
This information was brought to you by Cision http://news.cision.com
http://news.cision.com/nordic-nanovector/r/nordic-nanovector-to-present-at-the-china-healthcare-investing---partnering-symposium-in-china-and-s,c2469759
View original content:http://www.prnewswire.com/news-releases/nordic-nanovector-to-present-at-the-china-healthcare-investing-and-partnering-symposium-in-china-and-stifel-nordic-healthcare-seminar-in-london-300612098.html
SOURCE Nordic Nanovector
